Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2163185 Target Snapshot

NAD-dependent protein lipoamidase sirtuin-4, mitochondrial · SINGLE PROTEIN · Homo sapiens

69Compounds
15Assays
1Approved Drugs
28.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt Q9Y6E7. Use UniProt Q9Y6E7 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q9Y6E7 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats NAD-dependent protein lipoamidase sirtuin-4, mitochondrial as ChEMBL target CHEMBL2163185, mapped to UniProt Q9Y6E7. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
NAD-dependent protein lipoamidase sirtuin-4, mitochondrial
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2163185
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q9Y6E7
NAD-dependent protein lipoamidase sirtuin-4, mitochondrial
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether NAD-dependent protein lipoamidase sirtuin-4, mitochondrial is the right protein anchor across sources, using UniProt Q9Y6E7 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelNAD-dependent protein lipoamidase sirtuin-4, mitochondrial
UniProt AccessionQ9Y6E7
Component TypeProtein
Sequence Length314 aa

NAD-dependent protein lipoamidase sirtuin-4, mitochondrial

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as NAD-dependent protein lipoamidase sirtuin-4, mitochondrial, mapped to UniProt Q9Y6E7. Sequence length is 314 aa.

Mapped IDQ9Y6E7
Review nameNAD-dependent protein lipoamidase sirtuin-4, mitochondrial
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

1
Approved
1
Phase III
Assay Mix

Activity Type Distribution

IC5028.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5574837 6.05 IC50 900.0 Preclinical
CHEMBL265502 5.7 IC50 2000.0 Clinical
CHEMBL5573193 5.0 IC50 10000.0 Preclinical
CHEMBL1140 4.89 IC50 13000.0 Approved
CHEMBL5579775 4.85 IC50 14000.0 Preclinical
CHEMBL5591891 4.8 IC50 16000.0 Preclinical
CHEMBL5574249 4.7 IC50 20000.0 Preclinical
CHEMBL5573728 4.62 IC50 24000.0 Preclinical
CHEMBL5564142 4.48 IC50 33000.0 Preclinical
CHEMBL5594752 4.48 IC50 33000.0 Preclinical
Distribution

pChEMBL Value Distribution

1
5.0
1
5.5
1
6.0
0
6.5
0
7.0
0
7.5
0
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

15
Total Assays
18
Tested Compounds
1
Assay Types
Binding — 15 assays, 18 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 8 18 4.7
single protein format 5 0
assay format 2 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine